FOR adults with type 2 diabetes, along with diet and exercise
In a separate study
designed to evaluate
lowering, JARDIANCE significantly reduced A1C
In addition to lowering A1C, JARDIANCE significantly reduced weight and SBP*
-2.8% (10 mg)
-3.2% (25 mg)
VS -0.4% (placebo)
-2.6 mm Hg (10 mg)||
-3.4 mm Hg (25 mg)¶
*JARDIANCE is not indicated for weight loss or blood pressure management. Weight and SBP change were secondary endpoints.1
†A1C reduction: Difference from placebo (adjusted mean) was -0.7% and -0.9% for JARDIANCE 10 mg and 25 mg, respectively.
‡Weight change: Difference from placebo (adjusted mean) was -2.5% and -2.8% for JARDIANCE 10 mg and 25 mg, respectively. Mean baseline=172 lb; 172 lb; 172 lb.
§SBP mean baseline: 133.0 mm Hg, 129.9 mm Hg, and 130.0 mm Hg for JARDIANCE 10 mg, 25 mg, and placebo, respectively.1
SBP=systolic blood pressure.
Monotherapy Study Design: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of JARDIANCE (10 mg, 25 mg) administered orally over 24 weeks in drug-naïve patients with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise. Six hundred seventy-six treated patients received placebo (N=228), JARDIANCE 10 mg (N=224), or JARDIANCE 25 mg (N=224). The primary endpoint was A1C change from baseline. Weight change and blood pressure change from baseline were secondary endpoints.1